Credit Suisse analyst Martin Auster raised his price target for Alexion to $154 from $149 saying the resolution of overhangs on the shares supports upside, namely if a global 1210 switch strategy is viable given Soliris EU IP uncertainty and what will drive long-term growth for Alexion. The analyst expects partial or full resolution of the first overhang as investors recognize that biosimilar risk may largely be limited to the PNH indication, and lackluster competitive C5 data and probable biosimilar pushouts suggest bearish timeline assumptions are low risk, likely allowing ample time to convert the market to 1210 from Soliris. Auster reiterates an Outperform rating on the shares.